Novo Nordisk's sales increased by 24% in Danish kroner and by 25% at constant exchange rates to DKK 133.4 billion in the first six months of 2024

Financial Performance - Operating profit increased by 18% in Danish kroner and by 19% at constant exchange rates (CER) to DKK 57.8 billion, despite an impairment loss of DKK 5.7 billion related to ocedurenone [1] - Net sales grew by 24% in Danish kroner (25% at CER) to DKK 133.4 billion, with net profit increasing by 16% to DKK 45.5 billion [3] - Diluted earnings per share rose by 17% to DKK 10.17 [3] Regional and Product Sales - North America Operations sales increased by 36% in Danish kroner (36% at CER), driven by gross-to-net sales adjustments in the US [2] - International Operations sales grew by 9% in Danish kroner (11% at CER) [2] - Diabetes and Obesity care sales surged by 26% in Danish kroner (27% at CER) to DKK 125.0 billion, with GLP-1 diabetes sales up 32% and Obesity care sales up 37% to DKK 24.9 billion [2] - Rare disease sales declined by 4% in Danish kroner (3% at CER) [2] Research and Development - The phase 3 FRONTIER 2 trial for Mim8 demonstrated superior reduction of treated bleeding episodes in haemophilia A patients [2] - The ocedurenone CLARION-CKD phase 3 trial was stopped due to failure to meet the primary endpoint [2] - The FDA issued a Complete Response Letter for insulin icodec in July 2024 [2] - A positive CHMP opinion was received for updating the Wegovy® label to reflect cardiovascular risk reduction in the EU [2] Outlook - Sales growth for 2024 is now expected to be 22-28% at CER, with operating profit growth projected at 20-28% at CER [2] - Growth reported in Danish kroner is expected to be 1 percentage point lower than CER growth for both sales and operating profit [2] Leadership Commentary - The CEO highlighted strong sales growth driven by increased demand for GLP-1-based diabetes and obesity treatments, as well as positive R&D developments including Mim8 trial results and the Wegovy® label extension recommendation [4]